L. Thaker
This is a likely match — the affiliation was inferred from OpenAlex, ORCID, and web sources but has not been fully confirmed. Treat with appropriate caution.
Researcher
Also affiliated: University of Wisconsin–Madison (2026); New York Hospital Queens (2026); Presbyterian Hospital (2026); Government Medical College (2025–2026)
Faculty Researcher
Research Areas
Biography and Research Information
OverviewAI-generated summary
L. Thaker's research focuses on the analysis of clinical data to understand disease trends, treatment efficacy, and health disparities. Recent work includes systematic reviews and meta-analyses examining the impact of various therapeutic interventions. This includes investigating the efficacy of adding panitumumab to chemotherapy for metastatic colorectal cancer, evaluating dual therapy versus quadruple therapy for *Helicobacter pylori* eradication, and assessing the therapeutic effects of dapagliflozin on liver fibrosis and metabolic parameters in patients with metabolic dysfunction-associated steatotic liver disease. Additional research has analyzed trends and disparities in procedure-related mortality among older U.S. adults with digestive system malignancies using the CDC WONDER database, and compared the efficacy and safety of Factor XIa and Xa inhibitors for stroke prevention in patients with atrial fibrillation.
Metrics
- Publications: 22
Selected Publications
-
E-93 | Population-level Impact of Advancing Valvular Interventions on Mortality from Atrial Fibrillation and Flutter Among Adults with Nonrheumatic Valvular Heart Disease in the United States: A CDC-WONDER Analysis from 1999-2023 (2026)
Collaboration Network
Top Collaborators
- E-93 | Population-level Impact of Advancing Valvular Interventions on Mortality from Atrial Fibrillation and Flutter Among Adults with Nonrheumatic Valvular Heart Disease in the United States: A CDC-WONDER Analysis from 1999-2023
- E-93 | Population-level Impact of Advancing Valvular Interventions on Mortality from Atrial Fibrillation and Flutter Among Adults with Nonrheumatic Valvular Heart Disease in the United States: A CDC-WONDER Analysis from 1999-2023
- E-93 | Population-level Impact of Advancing Valvular Interventions on Mortality from Atrial Fibrillation and Flutter Among Adults with Nonrheumatic Valvular Heart Disease in the United States: A CDC-WONDER Analysis from 1999-2023
- E-93 | Population-level Impact of Advancing Valvular Interventions on Mortality from Atrial Fibrillation and Flutter Among Adults with Nonrheumatic Valvular Heart Disease in the United States: A CDC-WONDER Analysis from 1999-2023
- E-93 | Population-level Impact of Advancing Valvular Interventions on Mortality from Atrial Fibrillation and Flutter Among Adults with Nonrheumatic Valvular Heart Disease in the United States: A CDC-WONDER Analysis from 1999-2023
Similar Researchers
Based on overlapping research topics